Eli Lilly makes surprising retreat from major market
4 Articles
4 Articles
According to the Institute of the German Economy, the investments cancelled by the pharmaceutical companies Eli Lilly and Boehringer Ingelheim are a clear warning signal.
Eli Lilly makes surprising retreat from major market
Eli Lilly's (LLY) chairman and CEO Dave Ricks told German business newspaper Handelsblatt that Lilly would halve its planned investment in Germany, cutting its original 2.3 billion euro ($2.67 billion) commitment by roughly 50%. Reuters reported the announcement on June…
According to media reports, the two pharmaceutical companies Eli Lilly and Boehringer Ingelheim want to significantly reduce their planned investments in Germany if the intensified reimbursement regulations and higher discounts on medicines planned by the GKV-Spargesetz are actually implemented. Dr. Carola Reimann, CEO of the AOK-Bundesverband, sharply criticizes this announcement. On Friday, the law goes to the first reading in the Bundestag. {…
The announcements of the two pharmaceutical giants Eli Lilly and Boehringer Ingelheim to drastically reduce their planned billions of investments in Germany have made great waves in the state and federal policies. Both companies explicitly justify their steps with the planned GKV bill of the federal government and lack of planning security. BYC-News asked the regional Bundestag and state parliament members as well as the Mainz Ministry of Econom…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
